Article | August 24, 2022

Steps To Overcome Challenges Associated With Biologic Formulation Development

Source: Ascendia Pharma

Six years ago, two-thirds of all drugs in the development pipeline were small molecules. Today, while still leading the market, that number is just under 50% this year, according to an industry report conducted by PharmaCircle LLC in conjunction with Drug Development & Delivery. One technology that is growing, particularly in Phase I development, is biologics. In fact, nearly 45% of the 20,000+ drugs in the development pipeline are biologics.1

The rest of the decade is going to continue this trend. Biologics are projected to have 10.7% annual growth rate to 2025 and just under 10% for the five years after that.2 A more geriatric population, rising need for immunology, and government initiatives are three of the main reasons attributing to this growth.

This article explores guidance on the challenges posed by biologics, including overcoming degradation, establishing a stress test process, and the value of lipid nanoparticles (LNPs) and polymeric nanoparticles (NPs).

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.

Subscribe to Drug Delivery Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Delivery Leader